2. Search Result
Search Result
Results for "

rat aortic rings

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

9

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-Y0337A
    L-Cysteine hydrochloride
    10+ Cited Publications

    		 Endogenous Metabolite Metabolic Disease Cancer
    L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) .
    L-Cysteine hydrochloride
  • HY-W005255
    3-(3-Hydroxyphenyl)propionic acid

    		Endogenous Metabolite Cardiovascular Disease
    3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
    3-(3-Hydroxyphenyl)propionic acid
  • HY-101366
    A-61603

    		Adrenergic Receptor Endocrinology
    A-61603 is a selective α1A/α1a-adrenergic receptor agonist with Ki of 8.89 nM for rat submaxillary gland α1A, Ki of 30.5 nM for cloned bovine α1a. A-61603 potentiates Ca 2+ transients with EC50 of 6.9 nM. A-61603 stimulates phosphoinositide hydrolysis, induces contractile responses in vas deferens, prostate strips, and spleen strips, and exhibits low activity in aortic rings. A-61603 can be used for research on adrenergic function .
    A-61603
  • HY-Y1890B
    Cremophor EL-10

    		Biochemical Assay Reagents Others
    Cremophor EL-10 is a nonionic polyoxyethylene castor oil surfactant with multiple functions including organic solubilizer, mixed zinc anode corrosion inhibitor and dendrite growth inhibitor. By forming a physical barrier to block electrolyte contact and constructing oriented hydration channels to reduce the desolvation energy barrier of Zn 2+ , Cremophor EL-10 achieves a corrosion inhibition efficiency of over 99%. Cremophor EL-10 exerts no significant effects on the mitochondrial activity and cell viability of epithelial cells, making it suitable for in vitro drug delivery and biopharmaceutical research at concentrations ≤10% v/v. However, Cremophor EL-10 may induce sustained non-endothelium-dependent contraction in rat aortic rings and exert concentration-dependent inhibitory effects on acetylcholine-induced endothelium-dependent relaxation responses .
    Cremophor EL-10
  • HY-19732
    BIBS 39

    		Angiotensin Receptor Cardiovascular Disease
    BIBS 39 is a non-peptide angiotensin II receptor antagonist with antihypertensive activity, with higher affinity for the AT1 receptor than for the AT2 receptor. BIBS 39 competitively blocks AT1-mediated vasoconstriction and pressor responses, and effectively inhibits the activity of the renin-angiotensin-aldosterone system. BIBS 39 reduces diastolic blood pressure and induces mild, transient reflex tachycardia, with no off-target functional activity on the norepinephrine, K +/Cl − or vasopressin pathways. BIBS 39 can be used in research related to hypertension and renal hypertension [1][2 ][3].
    BIBS 39
  • HY-N13614
    Centaurein

    		Bacterial IFNAR Nuclear Factor of activated T Cells (NFAT) NF-κB Infection Inflammation/Immunology
    Centaurein, a flavonoid, is an IFN-γ promoter enhancer. Centaurein up-regulates the activity of NFAT and NF-κB enhancers. Centaurein increases the IFN-γ expression in T and NK cells and the serum IFN-γ level in mice. Centaureidin completely relaxes the contractions in intact rat aortic rings. Centaurein effectively protects mice against Listeria infection [1][2][3][4].
    Centaurein
  • HY-129665
    GS-389

    (±)-O,O-Dimethylcoclaurine

    		 Endogenous Metabolite Metabolic Disease
    GS 389 ((±)-O,O-Dimethylcoclaurine) is a tetrahydroisoquinoline. GS-389 inhibites Cyclic AMP and cyclic AMP dependent phosphodiesterases from rat atrial and ventricular tissue. GS-389 relaxes the contraction induced by phenylephrine and high K + in rat aortic rings .
    GS-389
  • HY-W005255R
    3-(3-Hydroxyphenyl)propionic acid (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease
    Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
    3-(3-Hydroxyphenyl)propionic acid (Standard)
  • HY-105572
    Moveltipril calcium

    MC-838 calcium

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Moveltipril calcium (MC-838 calcium) is an orally active angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moveltipril calcium binds via a stable thioester bond and exhibits relative resistance to enzymatic hydrolysis in rat liver homogenate. Moveltipril calcium effectively inhibits ACE extracted from rabbit lung in a concentration-dependent manner. Moveltipril calcium is able to highly specifically inhibit the contractile response to angiotensin-I (AI) in free rat aortic rings and guinea pig ileum preparations, while enhancing the contractile response to calcitonin .
    Moveltipril calcium
  • HY-P11259
    UPG-111

    		Urotensin Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system .
    UPG-111
  • HY-138166S
    Rosuvastatin lactone-d6

    		Isotope-Labeled Compounds Potassium Channel Drug Metabolite NO Synthase Cardiovascular Disease
    Rosuvastatin lactone-d6 is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .
    Rosuvastatin lactone-d6
  • HY-138166R
    Rosuvastatin lactone (Standard)

    		Reference Standards Potassium Channel Drug Metabolite NO Synthase Cardiovascular Disease
    Rosuvastatin lactone (Standard) is the analytical standard of Rosuvastatin lactone. This product is intended for research and analytical applications. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .
    Rosuvastatin lactone (Standard)
  • HY-Y0337AR
    L-Cysteine hydrochloride (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease Cancer
    L-Cysteine (hydrochloride) (Standard) is the analytical standard of L-Cysteine (hydrochloride). This product is intended for research and analytical applications. L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) [4].
    L-Cysteine hydrochloride (Standard)
  • HY-117991
    DW10075

    		VEGFR Cancer
    DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
    DW10075
  • HY-N15186
    Gymnoascolide A

    		Fungal Cardiovascular Disease
    Gymnoascolide A, identified as a fungal metabolite in M. filamentosa, demonstrates vasodilatory effects. At a concentration of 1 µM, it effectively inhibits contractions induced by calcium in isolated rat aortic rings .
    Gymnoascolide A
  • HY-N18103
    Anhydrohirundigenin

    		Others Cardiovascular Disease
    Anhydrohirundigenin (Compound 2) is a steroid. Anhydrohirundigenin can be isolated from the roots of Cynanchum stauntonii. Anhydrohirundigenin has no vasodilation activity .
    Anhydrohirundigenin
  • HY-P11258
    UPG-108

    		Urotensin Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    UPG-108, a peptide compound, is a non-competitive allosteric modulator of Urotensin II receptors (UTR). UPG-108 significantly enhances the efficacy of UTR agonists but reduces the potency of UTR agonists. UPG-111 efficiently induces calcium release and does not cause contraction of rat aortic rings without endothelial denudation. UPG-111 can be used to study various diseases related to the angiotensinergic system .
    UPG-108
  • HY-N17738
    Acetyljujuboside B

    		Calcium Channel Cardiovascular Disease Inflammation/Immunology
    Acetyljujuboside B is a saponin. Acetyljujuboside B can be isolated from seeds of Zizyphus jujuba Mill. var. spinosa. Acetyljujuboside B inhibits Ca 2+ influx. Acetyljujuboside B shows only sustained vasorelaxant effects, with no transient effect on NE-induced vasoconstrictions. Acetyljujuboside B inhibits histamine release from rat peritoneal exudate cells induced by the antigen-antibody reaction .
    Acetyljujuboside B

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: